A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Last updated: October 28, 2024
Sponsor: Pfizer
Overall Status: Completed

Phase

N/A

Condition

Multiple Myeloma

Lymphoproliferative Disorders

Leukemia

Treatment

Elranatamab

Standard of care

Clinical Study ID

NCT05932290
C1071031
  • Ages > 18
  • All Genders

Study Summary

This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3). The investigators will also use data from multiple real-world sources, representing the SOC in clinical practice. This study does not seek any participants for enrollment. The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help the investigators to know how well elranatamab can be used for RRMM treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 years and older at index date

  • Diagnosis of MM

  • Measurable disease according to IMWG criteria

  • ECOG performance status ≤2

  • Refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1anti-CD38 treatment (ie, triple-class refractory [TCR])

  • At least 1 treatment following their TCR eligibility

Exclusion

Exclusion Criteria:

  • Acute plasma cell leukemia

  • Amyloidosis

  • Smoldering MM

  • Stem cell transplant within 12 weeks of index or active graft versus host disease (GVHD)

  • Active malignancy within 3 years before index, except for basal cell or squamouscell skin cancer or carcinoma in situ

  • Administration with an investigational drug within 30 days prior to index

Study Design

Total Participants: 514
Treatment Group(s): 2
Primary Treatment: Elranatamab
Phase:
Study Start date:
June 01, 2023
Estimated Completion Date:
July 12, 2023

Connect with a study center

  • Pfizer

    New York, New York 10001
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.